OLP-1002

OLP-1002 is a peptide nucleic acid (PNA)-based antisense oligonucleotide drug developed by OliPass. It selectively inhibits the expression of the Nav1.7 sodium channel by targeting the SCN9A gene in neuronal cells, thereby reducing pain signaling. The drug is designed to replicate much of the phenotype observed in individuals with null mutations in SCN9A, who are congenitally insensitive to pain. OLP-1002 is administered subcutaneously and is currently under clinical development for several pain-related indications, including osteoarthritis pain (Phase II), neuropathic pain, rheumatoid arthritis pain, trigeminal neuralgia, and chemotherapy-induced peripheral neuropathy[1][2][3][4][5]. Its mechanism involves binding to pre-mRNA and inducing exon skipping or mRNA splice variant formation for therapeutic intervention[5].

Other names

SCN9A antisense oligonucleotideSCN-9A antisense oligonucleotideSCN 9A antisense oligonucleotideSCN9A-ASOSCN-9A-ASOSCN 9A-ASOOliPass SCN9A-ASO